"In our view, the ability to generate high quality wet-lab data is critical for advancement," analyst says in initiating ...

We recently compiled a list of the Top 10 Medical AI Stocks on Wall Street’s Radar. In this article, we are going to take a ...

Cathie Wood's ARK ETFs have made their daily trades public for Thursday, January 23rd, 2025, displaying a strategic shift in ...

Needham analyst has initiated coverage on Absci Corporation (NASDAQ:ABSI), a drug and target discovery company that harnesses ...

Absci recently received a $20 million PIPE investment from AMD that improves its runway and R&D platform with AI. See why I ...

Needham analyst Gil Blum initiated coverage of Absci (ABSI) with a Buy rating and $9 price target Absci “stands out from the pack due to its ...

H.C. Wainwright analyst Swayampakula Ramakanth maintained a Buy rating on AbSci (ABSI – Research Report) today and set a price target of $7.00.

Absci Stock Jumps As AMD Invests $20M To Boost AI Drug Discovery AI drug creation company Absci Corporation (NASDAQ:ABSI) shares are trading higher in premarket on Wednesday after the company ...

Investors sell off AMD shares despite the company's pivot to life sciences AI, following a rating downgrade by HSBC that ...

Insights from analysts' 12-month price targets are revealed, presenting an average target of $7.14, a high estimate of $10.00, and a low estimate of $5.00. This current average represents a 2.06% ...

Advanced Micro Devices is investing $20 million in Absci, a drug-discovery company based in Washington state, in a move aimed at selling its artificial intelligence chips in the healthcare sector.

Equities research analysts at Needham & Company LLC assumed coverage on shares of Absci (NASDAQ:ABSI – Get Free Report) in a ...